131 related articles for article (PubMed ID: 2125834)
1. In-vitro and in-vivo electrophysiologic effects of encainide.
Libersa C; Caron J; Rouet R
Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():567-72. PubMed ID: 2125834
[TBL] [Abstract][Full Text] [Related]
2. Electrophysiological effects of encainide and its metabolites in 11 patients.
Libersa CC; Lekieffre JP; Caron JF; Poirier JM; Pladys AM; Kacet S; Kher AR
J Cardiovasc Pharmacol; 1985; 7(6):1077-82. PubMed ID: 2418291
[TBL] [Abstract][Full Text] [Related]
3. Depression of maximum rate of depolarization of guinea-pig ventricular action potentials by metabolites of encainide.
Hemsworth PD; Campbell TJ
Br J Pharmacol; 1989 Jun; 97(2):619-25. PubMed ID: 2503225
[TBL] [Abstract][Full Text] [Related]
4. Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man.
Barbey JT; Thompson KA; Echt DS; Woosley RL; Roden DM
Circulation; 1988 Feb; 77(2):380-91. PubMed ID: 3123092
[TBL] [Abstract][Full Text] [Related]
5. Electrophysiological effects of encainide on isolated cardiac muscle and Purkinje fibers and on the Langendorff-perfused guinea-pig heart.
Carmeliet E
Eur J Pharmacol; 1980 Feb; 61(3):247-62. PubMed ID: 6767615
[TBL] [Abstract][Full Text] [Related]
6. Electrophysiologic effects of encainide following acute coronary occlusion in dogs.
Ro JH; Gillon J; Kupersmith J
J Cardiovasc Pharmacol; 1981; 3(3):532-40. PubMed ID: 6168834
[TBL] [Abstract][Full Text] [Related]
7. Acute electrophysiologic effects of sodium administration in dogs treated with O-desmethyl encainide.
Bajaj AK; Woosley RL; Roden DM
Circulation; 1989 Oct; 80(4):994-1002. PubMed ID: 2551538
[TBL] [Abstract][Full Text] [Related]
8. Resting and rate-dependent depression of maximum rate of depolarisation (Vmax) in guinea pig ventricular action potentials by mexiletine, disopyramide, and encainide.
Campbell TJ
J Cardiovasc Pharmacol; 1983; 5(2):291-6. PubMed ID: 6188905
[TBL] [Abstract][Full Text] [Related]
9. Temperature and voltage dependence of sodium channel blocking and unblocking by O-demethyl encainide in isolated guinea pig myocytes.
Johns JA; Anno T; Bennett PB; Snyders DJ; Hondeghem LM
J Cardiovasc Pharmacol; 1989 Jun; 13(6):826-35. PubMed ID: 2484076
[TBL] [Abstract][Full Text] [Related]
10. Electrophysiologic and clinical effects of oral encainide in paroxysmal atrioventricular node reentrant tachycardia.
Chimienti M; Li Bergolis M; Moizi M; Salerno JA
J Am Coll Cardiol; 1989 Oct; 14(4):992-8. PubMed ID: 2507613
[TBL] [Abstract][Full Text] [Related]
11. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.
Roden DM; Lee JT; Woosley RL; Echt DS
Circulation; 1989 Nov; 80(5):1247-58. PubMed ID: 2805262
[TBL] [Abstract][Full Text] [Related]
12. Electrophysiologic and clinical effects of intravenous and oral encainide in accessory atrioventricular pathway.
Kunze KP; Kuck KH; Schlüter M; Kuch B; Bleifeld W
Am J Cardiol; 1984 Aug; 54(3):323-9. PubMed ID: 6431796
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and electrophysiologic effects of encainide for atrioventricular nodal reentrant tachycardia.
Naccarelli GV; Jackman WM; Akhtar M; Rinkenberger RL; Friday KJ; Dougherty AH; Tchou P; Yeung-Lai-Wah JA
Am J Cardiol; 1988 Dec; 62(19):31L-36L. PubMed ID: 3144165
[TBL] [Abstract][Full Text] [Related]
14. Clinical electrophysiologic effects of encainide, a newly developed antiarrhythmic agent.
Sami M; Mason JW; Peters F; Harrison DC
Am J Cardiol; 1979 Sep; 44(3):526-32. PubMed ID: 474433
[TBL] [Abstract][Full Text] [Related]
15. Canine electrophysiology of encainide, a new antiarrhythmic drug.
Sami M; Mason JW; Oh G; Harrison DC
Am J Cardiol; 1979 Jun; 43(6):1149-54. PubMed ID: 443174
[TBL] [Abstract][Full Text] [Related]
16. Electrophysiology of oral encainide.
Jackman WM; Zipes DP; Naccarelli GV; Rinkenberger RL; Heger JJ; Prystowsky EN
Am J Cardiol; 1982 Apr; 49(5):1270-8. PubMed ID: 6801954
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome.
Prystowsky EN; Klein GJ; Rinkenberger RL; Heger JJ; Naccarelli GV; Zipes DP
Circulation; 1984 Feb; 69(2):278-87. PubMed ID: 6418407
[TBL] [Abstract][Full Text] [Related]
18. Electrophysiologic actions of O-demethyl encainide: an active metabolite.
Duff HJ; Dawson AK; Roden DM; Oates JA; Smith RF; Woosley RL
Circulation; 1983 Aug; 68(2):385-91. PubMed ID: 6861313
[TBL] [Abstract][Full Text] [Related]
19. Encainide for treatment of atrioventricular reciprocating tachycardia in the Wolff-Parkinson-White syndrome.
Miles WM; Zipes DP; Rinkenberger RL; Markel ML; Prystowsky EN; Dougherty AH; Heger JJ; Naccarelli GV
Am J Cardiol; 1988 Dec; 62(19):20L-25L. PubMed ID: 3144163
[TBL] [Abstract][Full Text] [Related]
20. Electrophysiologic evaluation of encainide with use of monophasic action potential recording.
Samuelsson RG; Harrison DC
Am J Cardiol; 1981 Nov; 48(5):871-6. PubMed ID: 6795911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
